DelveInsight Blog
Related Article
Leading the Charge: ULTOMIRIS’s Impact on NMOSD Relapse Prevention Strategies
ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) the potential to live relapse-free. The remarkable reduction in relapse risk observed in the CHAMPION-NMOSD t...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.